allergiesandasthmacontent Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis ... An article from: BIOTECH Patent News


Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis … An article from: BIOTECH Patent News

 Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis ... An article from: BIOTECH Patent News

buynow big Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis ... An article from: BIOTECH Patent News

List Price: $ 5.95

Price: $ 5.95

Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis … An article from: BIOTECH Patent News

This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on January 1, 2000. The length of the article is 544 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis Pharmaceuticals Inc.)(Brief Article)
Publication: BIOTECH Patent News (Newsletter)
Date: January 1, 2000
Publisher: Biotech Patent News
Volume: 14 Issue: 1 Page: NA

Article Type: Brief Article

Distributed by Thomson Gale

Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis … An article from: BIOTECH Patent News

Disclaimer: This site is a paid affiliate of Amazon.com


Related posts:

  1. Lotus Pharmaceuticals Obtains Patent and Exclusive Production Rights to Laevo-Bambutero Asthma Treatment.: An article from: BIOTECH Patent News Lotus Pharmaceuticals Obtains Patent and Exclusive Production Rights to Laevo-Bambutero...
  2. Parents and children disagree on asthma’s impact: lowest level of agreement, 69%, involved frustration with asthma treatments, activity limits.(Across … An article from: Clinical Psychiatry News Reviews Parents and children disagree on asthma’s impact: lowest level of...
  3. Asthma treatment fell short of guidelines in past decade.(PULMONARY MEDICINE): An article from: Family Practice News Asthma treatment fell short of guidelines in past decade.(PULMONARY MEDICINE):...
  4. Female fetuses may increase maternal asthma symptoms.(Women’s Health)(Brief Article): An article from: Family Practice News Female fetuses may increase maternal asthma symptoms.(Women’s Health)(Brief Article): An...

Related posts brought to you by Yet Another Related Posts Plugin.

Leave a Reply

Spam protection by WP Captcha-Free



Switch to our mobile site